Yanina Zborovskaya
Family · Rolling Meadows, ILNPI 1033402888
Payments from drug & device makers
Across 58 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$320
- Merck$152
- Genentech USA, Inc.$128
- Incyte Corporation$116
- Lilly USA, LLC$80
- Johnson & Johnson$41
- plus $444 from 19 others
What the payments were for
- Food & beverage$1,18392%
- Education$998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $320 |
| Merck | 8 | $152 |
| Genentech USA, Inc. | 5 | $128 |
| Incyte Corporation | 2 | $116 |
| Lilly USA, LLC | 3 | $80 |
| Johnson & Johnson | 2 | $41 |
| Seagen Inc. | 2 | $38 |
| GSK | 2 | $37 |
| Immunocore Limited | 1 | $30 |
| Pfizer | 2 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $29 |
| Bristol Myers Squibb | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| AbbVie | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Iovance Biotherapeutics, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $19 |
| Gilead | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Bayer | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
How this compares
$1,282 in reported general payments places this provider in the 75th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 24 | $407,164 |
| IbrancePalbociclib | 23 | $339,030 |
| CalquenceAcalabrutinib Maleate | 33 | $334,051 |
| JakafiRuxolitinib Phosphate | 20 | $220,884 |
| KisqaliRibociclib Succinate | 13 | $214,325 |
| XtandiEnzalutamide | 13 | $178,617 |
| TafinlarDabrafenib Mesylate | 13 | $171,819 |
| VenclextaVenetoclax | 11 | $151,790 |
| MekinistTrametinib Dimethyl Sulfoxide | 13 | $109,622 |
| XareltoRivaroxaban | 51 | $42,706 |
| EliquisApixaban | 62 | $37,503 |
| Abiraterone Acetate | 20 | $27,743 |
| Imatinib Mesylate | 13 | $15,048 |
| Exemestane | 22 | $4,864 |
| Fentanyl | 20 | $3,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tafinlar, Mekinist | $320 | $495,76639 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $24 | $407,16424 claims |
| PfizerIbrance, Eliquis | $30 | $376,53385 claims |
| AstraZenecaCalquence | $15 | $334,05133 claims |
| Incyte CorporationJakafi | $116 | $220,88420 claims |
| AbbVieVenclexta | $25 | $151,79011 claims |
| Johnson & JohnsonXarelto | $41 | $42,70651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,941 family providers in Illinois.
Other family in Rolling Meadows
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.